The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments

The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders’ perceptions.

Methods

We conducted a systematic literature search in MEDLINE from 2000 to April 2019, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology, and completed it with a manual search of other publications (mainly grey literature). The search was restricted to publications with English abstracts; the initial identification of articles was restricted to the title, abstract and key words fields. The geographical scope was not restricted.

Results

Over 20 studies proposed different taxonomies of risk-sharing contracts, which can be summarised as financial and paying-for-performance agreements. Theoretical studies modelling the incentives to implement risk-sharing agreements are scarce; they addressed different types of contracts and regulatory contexts, characterizing the drug prices and the optimal strategies of the involved agents. Empirical studies describing specific agreements are abundant and referred to different geographical contexts; however, few articles showed the economic results and assessed the value of such contracts. Stakeholders’ perceptions of risk-sharing contracting were favourable, but little is known about the economic and clinical advantages of specific agreements. Whether risk-sharing contracts have yielded the desired results for healthcare systems remains uncertain.

Conclusion

Risk-sharing contracts are increasingly used, although the lack of transparency and aggregated registries makes it difficult to learn from these experiences and assess their impact on healthcare systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Rent this article via DeepDyve

Similar content being viewed by others

Performance-Based Risk-Sharing Arrangements: An Updated International Review

Article 10 July 2017

Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia

Article Open access 10 June 2021

Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists

Article Open access 17 July 2019

Explore related subjects

Data Availability

No underlying data exist for this article as it is based on a review of other published studies.

References

  1. Yu JS, Chin L, Oh J, Farias J. Performance-based risk-sharing arrangements for pharmaceutical products in the United States: a systematic review. J Manag Care Spec Pharm. 2017;23(10):1028–40. PubMedGoogle Scholar
  2. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179–90. ArticlePubMedGoogle Scholar
  3. Garrison LJ, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr P, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance based risk-sharing arrangements task force. Value Health. 2013;16:703–19. ArticlePubMedGoogle Scholar
  4. Kanavos P, Ferrario A, Tafuri G, Siviero P. Managing risk and uncertainty in health technology introduction: the role of managed entry agreements. Glob Policy. 2017;8(S2):84–92. ArticleGoogle Scholar
  5. Lu CY, Ritchie J, Williams K, Day R. The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia. Aust N Z Health Policy. 2007;4:26. ArticleGoogle Scholar
  6. Morgan SG, Thomson PA, Daw JR, Friesen M. Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy. 2013;112:248–54. ArticlePubMedGoogle Scholar
  7. Zaric GS, O’Brien BJ. Analysis of a pharmaceutical risk sharing agreement based on the purchaser’s total budget. Health Econ. 2005;14:793–803. ArticlePubMedGoogle Scholar
  8. Barros PP. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ. 2011;20(4):461–70. ArticlePubMedGoogle Scholar
  9. Towse A, Garrison LP. Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 2010;28:93–102. ArticlePubMedGoogle Scholar
  10. Stafinski T, McCabe C, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics. 2010;28:113–42. ArticlePubMedGoogle Scholar
  11. McCabe CJ, Stafinski T, Edlin R, Menon D, Behalf Banff AEDS. Access with evidence development schemes a framework for description and evaluation. Pharmacoeconomics. 2010;28:143–52. ArticlePubMedGoogle Scholar
  12. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153. ArticlePubMedPubMed CentralGoogle Scholar
  13. Jaroslawski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res. 2011;11:259. ArticlePubMedPubMed CentralGoogle Scholar
  14. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9. ArticlePubMedGoogle Scholar
  15. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2008;26(7):551–6. ArticlePubMedGoogle Scholar
  16. Breckenridge A, Walley T. Risk sharing and payment by results. Clin Pharmacol Ther. 2008;83(5):666–7. ArticleCASPubMedGoogle Scholar
  17. Carapinha JL. Setting the stage for risk-sharing agreements: international experiences and outcomes-based reimbursement. S Afr Fam Pract. 2008;50(4):62–5. Google Scholar
  18. Espín J, Oliva J, Rodríguez-Barrios JM. Esquemas innovadores de mejora del acceso al mercado de nuevas tecnologías: Los acuerdos de riesgo compartido. Gac Sanit. 2010;24(6):491–7. ArticlePubMedGoogle Scholar
  19. Barros PP. Pharmaceutical policies in European countries. Adv Health Econ Health Serv Res. 2010;22:3–27. ArticlePubMedGoogle Scholar
  20. Klemp M, Frønsdal K, Facey K, on behalf of the HTAi Policy Forum. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011;2011(27):77–83. ArticleGoogle Scholar
  21. Campillo-Artero C, Del Llano J, Poveda JL. Contratos de riesgo compartido, ¿con medicamentos huérfanos? Farm Hosp. 2012;36(6):455–63. CASPubMedGoogle Scholar
  22. Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013;8:198. ArticlePubMedPubMed CentralGoogle Scholar
  23. Paredes Fernández DM, Lenz Alcayaga RC. Acuerdos de Riesgo Compartido: Lecciones Para su Diseño e Implementación a la Luz de la Experiencia Internacional. Value Health Reg Issues. 2019;20:51–9. ArticleGoogle Scholar
  24. Coulton L, Annemans L, Carter R, Herrera MB, Thabrany H, Lim J, et al. Outcomes-based risk-sharing schemes: is there a potential role in the Asia-Pacific markets? Health Outcomes Res Med. 2012;3(4):e205–19. ArticleGoogle Scholar
  25. Launois R, Ethgen O. Risk-sharing agreements: Choice of study design and assessment criteria [Contrats de risk-sharing: Choix des schémas d’étude et des critères de jugement. Ann Pharm Fr. 2013;71(5):346–57. ArticleCASPubMedGoogle Scholar
  26. Zaric GS, Zhang H, Mahjoub R. Modeling risk sharing agreements and patient access schemes. In: Zaric G, editor. Operations research and health care policy. International series in operations research and management science, vol. 190. New York: Springer; 2013. p. 295–310. Google Scholar
  27. Zhang H, Zaric GS, Huang T. Optimal design of a pharmaceutical price-volume agreement under asymmetric information about expected market size. Prod Oper Manag. 2011;20(3):334–46. ArticleGoogle Scholar
  28. Gavious A, Greenberg D, Hammerman A, Segev E. Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach. Eur J Heal Econ. 2014;15(5):553–61. ArticleGoogle Scholar
  29. Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value Health. 2009;12:838–45. ArticlePubMedGoogle Scholar
  30. Mahjoub R, Odegaard F, Zaric GS. Health-based pharmaceutical pay-for-performance risk-sharing agreements. J Oper Res Soc. 2014;65(4):588–604. ArticleGoogle Scholar
  31. Zhang H, Zaric GS. Using price–volume agreements to manage pharmaceutical leakage and off-label promotion. Eur J Health Econ. 2015;16(7):747–61. ArticlePubMedGoogle Scholar
  32. Gandjour A. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2009;27:431–2. ArticlePubMedGoogle Scholar
  33. Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law. 2011;6(3):391–403. ArticlePubMedGoogle Scholar
  34. Levaggi R, Moretto M, Pertile P. The dynamics of pharmaceutical regulation and R&D investments. J Public Econ Theory. 2017;19(1):121–41. ArticleGoogle Scholar
  35. Mahjoub R, Ødegaard F, Zaric GS. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Econ. 2018;27(1):e15–25. ArticlePubMedGoogle Scholar
  36. Antonanzas F, Rodríguez-Ibeas R, Juárez-Castelló C. Personalized medicine and pay-for-performance: should pharmaceutical firms be fully penalized when treatment fails? Pharmacoeconomics. 2018;36(7):733–43. ArticlePubMedGoogle Scholar
  37. Garattini L, Casadei G. Risk sharing agreements: what lessons from Italy? Int J Technol Assess Health Care. 2011;27(2):169–72. ArticlePubMedGoogle Scholar
  38. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMiNet; 2013. Google Scholar
  39. Garattini L, Curto A, Van de Vooren K. Italian risk sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16:1–3. ArticlePubMedGoogle Scholar
  40. Carlson JJ, Chen S, Garrison LP. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017;35(10):1063–72. ArticlePubMedGoogle Scholar
  41. Ferrario A, Araja D, Bochenek T, Čatic T, Dannkó D, Dimitrova M, et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35(12):1271–85. ArticlePubMedPubMed CentralGoogle Scholar
  42. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47. ArticlePubMedGoogle Scholar
  43. Lu CY, Lupton C, Rakowsky S, Babar ZUD, Ross-Degnan D, Wagner AK. Patient access schemes in Asia-pacific markets: current experience and future potential. J Pharm Policy Pract. 2015;8(1):6. ArticlePubMedPubMed CentralGoogle Scholar
  44. Piatkiewicz TJ, Traulsen JM, Holm-Larsen T. Risk-sharing agreements in the EU: a systematic review of major trends. Pharmacoecon Open. 2018;2(2):109–23. ArticlePubMedGoogle Scholar
  45. Darbà J, Ascanio M. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia. Expert Rev Pharmacoecon Outcomes Res. 2019. https://doi.org/10.1080/14737167.2019.1587296. ArticlePubMedGoogle Scholar
  46. Maskineh C, Nasser SC. Managed entry agreements for pharmaceutical products in middle East and North African countries: payer and manufacturer experience and outlook. Value Health Reg Issues. 2018;16:33–8. ArticlePubMedGoogle Scholar
  47. Campillo-Artero C, Kovacs F. The use of risk sharing tools for post adoption surveillance of a non-pharmacological technology in routine practice: results after one year. BMC Health Serv Res. 2013;13:181. https://doi.org/10.1186/1472-6963-13-181. ArticlePubMedPubMed CentralGoogle Scholar
  48. AIFA Agenzia Italiana del Farmaco. http://www.aifa.gov.it/content/comunicazioni-managed-entry-agreements-mea. Accessed 4 Mar 2019.
  49. NICE Patient access schemes liaison unit. https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit. Accessed 5 Mar 2019.
  50. Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP Jr. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy. 2014;12(3):231–8. ArticlePubMedGoogle Scholar
  51. Pickin M, Cooper CL, Chater T, O’Hagan A, Abrams KR, Cooper NJ, et al. The multiple sclerosis risk-sharing scheme monitoring study-early results and lessons for the future. BMC Neurol. 2009;9:1. ArticlePubMedPubMed CentralGoogle Scholar
  52. Fagnani F, Pham T, Claudepierre P, et al. Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France. J Med Econ. 2016;19(8):812–21. ArticlePubMedGoogle Scholar
  53. Soini E, Asseburg C, Taiha M, Puolakka K, Purcaru O, Luosujärvi R. Modeled health economic impact of a hypothetical certolizumab pegol risk-sharing scheme for patients with moderate-to-severe rheumatoid arthritis in Finland. Adv Ther. 2017;34(10):2316–32. ArticlePubMedPubMed CentralGoogle Scholar
  54. Calleja MA, Martín M, García C, Rubio-Terrés C, Rubio-Rodríguez D. Análisis del impacto económico del acuerdo de riesgo compartido clínico (ARCC) con certolizumab pegol (Cimzia ® ) para el tratamiento de la artritis reumatoide. Rev Esp Econ Salud. 2016;11(2):178–91. Google Scholar
  55. Clopes A, Gasol M, Cajal R, Segú L, Crespo R, Mora R, et al. Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. J Med Econ. 2017;20(1):1–7. ArticlePubMedGoogle Scholar
  56. Makady A, van Veelen A, de Boer A, Hillege H, Klungel OH, Goettsch W. Implementing managed entry agreements in practice: the Dutch reality check. Health Policy. 2019;123(3):267–74. ArticleCASPubMedGoogle Scholar
  57. Han E, Park SY, Lee EK. Assessment of the price-volume agreement program in South Korea. Health Policy. 2016;120(10):1209–15. ArticlePubMedGoogle Scholar
  58. Park SY, Han E, Kim J, Lee EK. Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea. Health Policy. 2016;120(8):678–774. ArticleGoogle Scholar
  59. Dunlop WCN, Staufer A, Levy P, Edwards GJ. Innovative pharmaceutical pricing agreements in five European markets: a survey of stakeholder attitudes and experience. Health Policy. 2018;122(5):528–32. ArticlePubMedGoogle Scholar
  60. Rojas P, Antonanzas F. Los contratos de riesgo compartido en el Sistema Nacional de Salud: percepciones de los profesionales sanitarios. Rev Esp Salud Pública. 2018;92(1):1–20. Google Scholar
  61. Kolasa K, Kalo Z, Hornby E. Research Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):145–55. ArticlePubMedGoogle Scholar
  62. Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, et al. Outcomes-based contracting experience: research findings from US and European stakeholders. J Manag Care Spec Pharm. 2017;23(10):1018–26. PubMedGoogle Scholar
  63. Lam MT, De Longhi C, Turnbull J, Lam HR, et al. Has Embase replaced Medline since coverage expansion? J Med Libr Assess. 2018;106(2):227–33. Google Scholar

Acknowledgements

The authors thank the editor and three anonymous referees for their comments and suggestions.